An observational study in Intracranial Aneurysms, sponsored by Acandis GmbH. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-23.
Sponsored by Acandis GmbH · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Intracranial Aneurysm with a site in France — 19 open to participants now, 26 under way, 1 of them phase 3. Intracranial Aneurysm · France.
Among the 66 studies in Intracranial Aneurysm with a site in France, this one is the 36th largest by planned enrollment of the 43 observational ones that give a count, is one of 4 that started in 2021, is one of 43 observational ones, reaches primary completion later than 7 of the 25 other live ones, and was the 60th registered.
419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.
Browse Intracranial Aneurysm studies →19 of the 66 studies in Intracranial Aneurysm with a site in France are open now. Recruiting first, the newest first:
Resolve Stroke · Sites in France
Ages 18+
CHU de Reims · Sites in France
Ages 18+
Sim&Cure · Sites in France
Ages 18+
Phenox GmbH · Sites in France, Germany, Italy and 2 more countries
Hospices Civils de Lyon · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 200 across 191 observational studies indexed under Intracranial Aneurysm.
Median enrollment 171 across the 23 interventional studies, 206 across the 43 observational. Of the 37 that completed or were terminated, 5 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 66 have an industry lead sponsor. The 10 most frequent:
Acandis GmbH is the lead sponsor of 11 studies on the registry; 7 are open to participants now.
Acandis GmbH has 3 studies filed under Intracranial Aneurysm — fewer than ten, so there is no comparison to draw.
4 of the studies in Intracranial Aneurysm with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04192955Phase 3University of CalgaryEvaluating Oral Peri-operative Acetylsalicylic Acid in Subjects Undergoing Endovascular Coiling-only of Unruptured Brain Aneurysms | 2027-03 |
| NCT07864389Resolve StrokeMultimodal Approach Feasability Study for Untreated and Unruptured Intracranial Aneurysms | 2026-11 |
| NCT06940934Acandis GmbHPost-Market Product Surveillance of Intracranial ANeurysms Treated With Commercial ReGistered ACANDIS Devices in FrancE | 2026-12 |
| NCT06689410Nantes University HospitalMultimodal Biocollection Linked to the French Register of Intracranial Aneurysms | 2027-03-25 |
Add all 4 to your calendar (.ics) → With an account.
Among the 66 studies in Intracranial Aneurysm with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aims of this clinical data collection are to investigate mortality, morbidity and neurological outcome 12 months after treatment of subject's intracranial aneurysm(s) and additionally to evaluate potential residual risks associated with the use of the commercial device(s) and to ensure the long-term safety and performance of Acandis Device(s) after its placing on the French market. On top of this, these cohorts will generate data for getting the renewal of the device's reimbursement on the French market.
Each cohort will consist of subjects with an intracranial aneurysm whom the physician wishes to treat with one or more Acandis devices.
Each subject will be followed according to the standard of care within the participating sites.
All treated (and intended to treat with at least 1 Acandis device inserted) cases will be captured in the ANCRAGE study database, from the date of agreement with French authorities; that means it will be a consecutive prospective enrollment to demonstrate the exhaustivity at the site, even the cases are captured in the database retrospectively.
There is a minimum of 50 consecutive cases to be enrolled per device family, from the time the device has been put on the French market and until the needed report to the authorities (for instance the renewal of the device registration/reimbursement).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Morbi-mortality related to the device and/or procedure at 12+/-3 months post implantation
Morbi-mortality related to the device and/or procedure at 12+/-3 months post implantation, defined as a mRS \>/= 3 for the subjects with a baseline mRS between 0 and 2 or mRS increase of 1 point for subjects with a baseline mRS greater than 2.
Time frame: 12+/-3 months after treatment
Started Dec 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.
Of 105 observational studies under Intracranial Aneurysm, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 145. This study's planned 60 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acandis GmbH